Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999

Djuretic, T; Herbert, Jeff; Drobniewski, Francis; Yates, M.D.; Smith, E. Grace; Magee, Jeffrey C.; Williams, Roger J.; Flanagan, Peter R.; Watt, B.; Rayner, A.; Crowe, M.; Chadwick, Maureen V.; Middleton, Andrew M.; Watson, John M.

doi:10.1136/thorax.57.6.477

Cited by 67 publications

(52 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In England and Wales multidrug resistant isolates (resistant to at least isoniazid and rifampicin) have remained uncommon with >2 % of isolates multidrug resistant [2,3]. However, these cases are important because they are difficult to treat and consume valuable health resources [4].…”

Section: Introductionmentioning

confidence: 99%

“…However, these cases are important because they are difficult to treat and consume valuable health resources [4]. Approximately 6% of isolates in England and Wales are isoniazid resistant [2,3].…”

Section: Introductionmentioning

confidence: 99%

“…Some studies have found resistance to be associated with cavitatory pulmonary disease [11], and most studies from developed countries (particularly the United States) have found relationships with ethnic groupings [5,7], foreign birth [7,[12][13][14] and urban centres [13]. In the United Kingdom surveillance data from England and Wales have generally shown an excess of drug-resistant cases in London, in HIV-positive cases, those not born in the United Kingdom and sometimes in non-white ethnic groups [2,3,15].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance

Conaty

Hayward

Story³

et al. 2004

Epidemiol. Infect.

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance

Conaty

Hayward

Story³

et al. 2004

Epidemiol. Infect.

View full text Add to dashboard Cite

“…Incidences were consistent with reported whole year isoniazid resistance of 6% and multi-drug resistant (MDR)-TB of 1.3%. 10 The 1990 JTC Treatment Guidelines 4 recommended 2HRZ/4HR with the addition of ethambutol in the initial phase in those at higher risk of isoniazid resistance, an 'opt-in' strategy. While some of the patients reported here were on treatment, the JTC updated their Guidelines and recommended 2HRZE/4HR, with ethambutol (E) omitted only in those defined as at low-risk of isoniazid resistance, an 'opt-out' strategy.…”

Section: Outcomementioning

confidence: 99%

The management of pulmonary and lymph node tuberculosis notified in England and Wales in 1998

Ormerod

Prescott

2003

Clinical Medicine

View full text Add to dashboard Cite

The management of pulmonary and lymph node tuberculosis notified in England and Wales in 1998 LP Ormerod and RJ Prescott ABSTRACT -The management of 1,337 cases of pulmonary tuberculosis and 422 cases of lymph node tuberculosis reported to the 1998 national notification survey was compared with the recommended standards of treatment. Most patients (84%) were under the care of thoracic physicians. Culture confirmation was obtained in 67.5% of pulmonary cases and 52% of lymph node cases. Drug resistance was reported in 7%, ranging from 3.3% in white patients to 7.9-8.2% in other ethnic groups. Only a minority of non-white ethnic patients received the recommended fourdrug initial phase of therapy. Non-standard durations of initial and/or continuation therapy were used in 35% of cases on recommended drug combinations. Thirty-nine (2.9%) pulmonary cases were diagnosed only at post-mortem and a further 96 died before the end of the survey period, 55 (4.3%) due to tuberculosis. The outcome for pulmonary disease, with 80% cured or completing treatment, compare favourably with European outcome data. Although overall outcome data were satisfactory, more patients should have received a four-drug initial phase, with more combination tablet use and better compliance monitoring. Outcome monitoring will henceforth be based mainly on the continuous enhanced surveillance system introduced since 1999.

show abstract

“…Los pacientes inmunocomprometidos tienen una mayor prevalencia de la tuberculosis que la población general (35) y también tienen más probabilidades de estar infectados con tuberculosis multirresistente (36). Además, el patrón de la enfermedad es diferente en pacientes inmunocomprometidos, que tienen una mayor prevalencia de afectación extrapulmonar.…”

Section: Factores De Riesgounclassified

Hallazgos radiológicos de la tuberculosis pulmonar y su correlación con la presencia de cultivo positivo para Mycobacterium tuberculosis

Ballester¹

View full text Add to dashboard Cite

Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999

Cited by 67 publications

References 15 publications

Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance

Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance

The management of pulmonary and lymph node tuberculosis notified in England and Wales in 1998

Hallazgos radiológicos de la tuberculosis pulmonar y su correlación con la presencia de cultivo positivo para Mycobacterium tuberculosis

Contact Info

Product

Resources

About